Based on these findings, targeting YAP1 holds therapeutic potential for CAF phenotype conversion: Selective ablation of YAP1 in ECM-CAFs could drive their transformation towards anti-tumorigenic Lym-CAFs, thereby enhancing the efficacy of anti-PD-1 antibody therapy in PCa. Here, YAP1 is linked to posterior cortical atrophy.